| 1 |
Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development
Weon‐Kyoo You, Thomas J. Schuetz, Sang Hoon Lee · Molecular Cancer Therapeutics
Open access |
12 Oct 2022 |
80 |
| 2 |
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
Eun-Sil Sung et al. · Molecular Therapy
Open access |
6 May 2022 |
80 |
| 3 |
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
Seongju Jeong et al. · Journal for ImmunoTherapy of Cancer
Open access |
Jul 2021 |
58 |
| 4 |
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 + tumor-infiltrating lymphocytes
Gihoon You et al. · Science Advances
Open access |
15 Jan 2021 |
57 |
| 5 |
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
Jing Gao, Zhengyi Wang, Wenqing Jiang et al. · Journal for ImmunoTherapy of Cancer
Open access |
Jun 2023 |
49 |
| 6 |
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Gihoon You, Jonghwa Won, Yangsoon Lee et al. · Vaccines
Open access |
2 Jul 2021 |
47 |
| 7 |
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
Dong-Hoon Yeom, Yo-Seob Lee, Ilhwan Ryu et al. · International Journal of Molecular Sciences
Open access |
29 Dec 2020 |
40 |
| 8 |
Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier
Jung-Won Shin et al. · Cell Reports Methods
Open access |
Nov 2022 |
35 |
| 9 |
Inhibitory effect of Gastrodia elata Blume extract on alpha-melanocyte stimulating hormone-induced melanogenesis in murine B16F10 melanoma
Eugene Shim, Eun-Ju Song, Kyoung Sook Choi et al. · Nutrition Research and Practice
Open access |
2017 |
26 |
| 10 |
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Geoffrey Yuyat Ku et al. · Clinical Cancer Research
Open access |
26 Jun 2025 |
20 |
| 11 |
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
Da-Hyun Kim, Seul Lee, Hyeok-Gu Kang et al. · BMB Reports
Open access |
30 Oct 2020 |
20 |
| 12 |
A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies
Sungwon An et al. · npj Parkinson s Disease
Open access |
22 Aug 2025 |
18 |
| 13 |
Enhanced cell growth, production, and mAb quality produced in Chinese hamster ovary-K1 cells by supplementing polyamine in the media
Da Eun Kang, Yeong Bin An, Yeunju Kim et al. · Applied Microbiology and Biotechnology
|
22 Mar 2023 |
17 |
| 14 |
Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
Eunhee Lee, Shinai Lee, Sumyeong Park et al. · Journal for ImmunoTherapy of Cancer
Open access |
Oct 2023 |
16 |
| 15 |
Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis
Jaeyun Jung, Seung Tae Kim, Jihoon Ko et al. · JCO Precision Oncology
Open access |
Jul 2023 |
16 |
| 16 |
Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
Seung Hyuck Jeon, Gihoon You, Junsik Park et al. · Clinical Cancer Research
|
30 Apr 2024 |
15 |
| 17 |
Genome-Wide CRISPR/Cas9 Screening Unveils a Novel Target ATF7IP–SETDB1 Complex for Enhancing Difficult-to-Express Protein Production
Su Hyun Kim, Jong-Ho Park, Sungwook Shin et al. · ACS Synthetic Biology
|
19 Jan 2024 |
14 |
| 18 |
Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy
Min-Sun Choi, Tae-Kyung Kim, Jin-Hyung Ahn et al. · Experimental Neurobiology
Open access |
28 Feb 2022 |
14 |
| 19 |
Localization of VEGF to Vascular ECM Is an Important Aspect of Tumor Angiogenesis
Weon‐Kyoo You, William B. Stallcup · Cancers
Open access |
28 Jul 2017 |
14 |
| 20 |
High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer
Youjin Kim, Sun‐ju Byeon, Joon-Young Hur et al. · Journal of Cancer
Open access |
2019 |
13 |
| 21 |
388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)
S.J. Klempner, Farshid Dayyani, Jeremy D. Kratz et al. · Annals of Oncology
Open access |
Jul 2025 |
11 |
| 22 |
N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
Min Ji Ko, Daehae Song, Ju Hee Kim et al. · mAbs
Open access |
2021 |
11 |
| 23 |
Evaluation of a lateral flow assay–based IFN-γ release assay as a point-of-care test for the diagnosis of latent tuberculosis infection
Hoon Hee Lee, Dong Hwan Choi, Jeong‐Ran Kim et al. · Clinical Rheumatology
Open access |
5 Mar 2021 |
8 |
| 24 |
Integrating a Microphysiological System and Physiologically Based Pharmacokinetic Modeling to Predict Human Responses to Diclofenac
Suein Choi, Jung-Hyun Lee, Okju Kim et al. · BioChip Journal
|
4 Apr 2025 |
7 |
| 25 |
Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety
Gihoon You, Jungwoo Choi, Chorong Yang et al. · mAbs
Open access |
6 Feb 2026 |
5 |
| 26 |
1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
S.J. Klempner, Lin Shen, D. Liu et al. · Annals of Oncology
Open access |
Sep 2024 |
5 |
| 27 |
Neoagarooligosaccharides improve non-alcoholic fatty liver disease by modulating lipid metabolism and Nrf2-related pathways
Subin Bae, Je Hyeon Lee, Su Jung Kim et al. · Journal of Functional Foods
Open access |
19 Mar 2025 |
4 |
| 28 |
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8 + T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment
Wonjun Son, Yangsoon Lee, Yelim Park et al. · Journal for ImmunoTherapy of Cancer
Open access |
Feb 2025 |
4 |
| 29 |
544P A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
Eungsang Lee, Hwa-Jee Chung, Y. Lee et al. · Annals of Oncology
Open access |
Sep 2021 |
3 |
| 30 |
Differential polyamine metabolism in CHO cell lines: Insights into cell growth and antibody quality
Da Eun Kang, Deepikka Senthilkumar, Jae Hong Jeon et al. · New Biotechnology
Open access |
24 Apr 2025 |
2 |
| 31 |
CLEC12A-directed immunocytokine with target cell–restricted IL-15 activity for treatment of acute myeloid leukemia
Boris Klimovich, Leonard Anton, Jinwon Jung et al. · Frontiers in Immunology
Open access |
27 Mar 2025 |
2 |
| 32 |
Population pharmacokinetic model of ABL001 / CTX ‐009 (anti‐ VEGF / DLL4 ) in adult cancer patients with solid tumor
Joo Young Na, Juyeun Jeon, Ki Young Huh et al. · Cancer Science
Open access |
7 Oct 2024 |
1 |
| 33 |
Cell line-specific impact of dexamethasone on the bioprocessing of Chinese hamster ovary cells
Yeong Bin An, Da Eun Kang, Jiseon Yoo et al. · Biotechnology and Bioprocess Engineering
|
23 Apr 2024 |
1 |
| 34 |
622MO An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients
E. Lee, Younghoon Lim, Sang Hoon Lee et al. · Annals of Oncology
Open access |
Sep 2022 |
1 |
| 35 |
Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1
Jung A. Kwon, Suyoun Lee, Juhee Kim et al. · mAbs
Open access |
12 Sep 2026 |
0 |
| 36 |
Harnessing Gradient Topography and Dual‐Mode Bioactive Delivery via Bone‐Adhesive Exosome Mimetics for Rotator Cuff Tendon–Bone Interface Repair
Jinsu Im, Jeong In Kim, Ju Yeon Kim et al. · Small
|
5 Aug 2026 |
0 |
| 37 |
Clinical‐Grade Human Induced Pluripotent Stem Cell‐Derived Neural Precursor Cells Restore Motor Function and Preserve Striatal Integrity in a Quinolinic Acid‐Lesioned Rat Model of Huntington's Disease
Hyeonjoong Jeon, Il-Shin Lee, Sanghun Lee et al. · Cell Proliferation
Open access |
26 Feb 2026 |
0 |
| 38 |
Systemic and Local Delivery of siRNA to the CNS and Periphery via Anti-IGF1R Antibody Conjugation
Mengnan Tian, Mehran Nikan, Miran Yoo et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
2 Feb 2026 |
0 |
| 39 |
257P Phase I clinical trial of ragistomig (ABL503/TJ-L14B: PD-L1 × 4-1BB bispecific antibody) Q6W dosing balances favorable safety and sustained efficacy through extended immunologic memory and reinvigoration of CD8+ T cells
G.S. Falchook, A.B. El-Khoueiry, J. Thomas et al. · Immuno-Oncology Technology
Open access |
Dec 2025 |
0 |
| 40 |
Grabody B, an IGF1R‐targeting Molecular Shuttle, Sustains Brain Penetration of Therapeutic Antibody in Aged Mice by Multiple, Novel Transcytosis Pathways
Sungwon An, Dongin Kim, Miran Yoo et al. · Alzheimer s & Dementia
Open access |
Dec 2025 |
0 |
| 41 |
Age-related Macular Degeneration patient deep phenotyping and whole genome sequencing analysis identifies coding variants linking small low-luminance visual deficit to fat storage defects
Sehyun Kim, Amy Stockwell, Han Qin et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
26 Jun 2022 |
0 |
| 42 |
Prevalence, Treatment Patterns, and Prognosis of Low Estrogen Receptor–Positive (1% to 10%) Breast Cancer: A Single Institution’s Experience in Korea
Yeon Hee Park, Vassiliki Karantza, Shawna R. Calhoun et al. · Research Square
PreprintOpen access |
13 May 2021 |
0 |